Regarding tumor-specific immune responses, tumor antigen-loaded DCs plus lenalidomide showed significantly increased percentages of NK cells (Figure 4A), CD4+ T cells (Figures 4B–4D) and CD8+ T cells (Figure 4E and 4F) compared with the other groups. This evidence concerns the gene CD8A and neoplasm.